OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	689
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	402
Regulation of the hippocampal translatome by Apoer2-ICD release	298
Altered trafficking of Kv1-Kvβ2 leads to neuronal hyperexcitability and memory deficits in amyloid-β pathology	269
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	253
Synaptic control of retinal ganglion cell survival and axon regeneration	203
Obesity-driven phosphatidylethanolamine dysregulation impairs neuroimmune crosstalk and accelerates Alzheimer’s pathogenesis	175
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	168
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	154
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	152
Tau interactome and RNA binding proteins in neurodegenerative diseases	141
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	137
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	125
Microglia sensing of peripheral signals that bridge the brain and body	120
Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice	119
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	116
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	115
Organelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases	112
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy	107
Understanding the genetic imperfections of Lewy body dementia	99
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	97
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	96
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	94
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	92
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	89

ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders	86
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	84
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	83
Transplantation of human iPSC-derived microglia ameliorates neuropathology and circuit dysfunction in progranulin-deficient mice	80
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	78
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	77
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	76
A ‘Tangled Web’ in the CNS: unraveling neutrophil extracellular traps in neurological disorders	75
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	74
Multi-omics insights into GBA1-associated Parkinson’s disease: interplay of genomics, transcriptomics, proteomics, and lipidomics	74
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	74
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	73
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	72
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	72
In Memoriam of Edward H. Koo, MD 1954–2025	72
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	71
Impaired nucleocytoplasmic transport in SOD1-mediated ALS	68
Standardized protocol to detect phosphorylated α-synuclein in skin biopsies: recommendations from an expert panel	68
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	66
Pharmacological restoration of impaired autophagy in retinal ganglion cells prevents abnormal mitochondrial accumulation and glaucomatous neurodegeneration	65
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	65
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	64
A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-clinically impaired participants: prelude for secondary preventive therapy in preclinical AD	62
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	62
Parkinson’s disease LRRK2 mutations dysregulate iron homeostasis and promote oxidative stress and ferroptosis in human neurons and astrocytes	62
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	61
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	60
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	60
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	59
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	58
Plasma platelet-derived growth factor receptor-β decrease correlates with blood-brain barrier damage in Alzheimer’s disease	58
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	57
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	57
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	57
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	57
Using mass spectrometry to validate mouse models of tauopathy	57
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	56
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	56
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	55
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	54
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	54
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	51
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	51
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	50
The endotoxin hypothesis of Alzheimer’s disease	49
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	49
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	48
Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review	47
Longitudinal multiphoton imaging of cerebral amyloid angiopathy in response to anti-ApoE4 immunotherapy in mice	47

APOE genotype influences on the brain metabolome of aging mice – role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype	47
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	46
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	46
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	45
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	45
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	44
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease	44
Sex specific molecular networks and key drivers of Alzheimer’s disease	44
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	43
Mitochondria transfer in neurological disorders: the key role of neuroglia	42
The complex lipidome as a driver of tissue-specific pathology in adrenoleukodystrophy	42
Mechanisms of astrocyte aging in reactivity and disease	42
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer’s disease	42
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	41
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	41
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	40
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	40
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	39
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	39
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	39
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	39
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	39
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology	38
Correction: Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis	38
The molecular fidelity of Aβ pathology in 5xFAD and AppNL−FPsen1P117L mice revealed by cryo-EM	38
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	38
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	37
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	37
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	37
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	37
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	37
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies	37
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	36
Elevated nuclear TDP-43 induces constitutive exon skipping	36
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	36
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease	36
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	36
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	36
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	36